Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868277 · ClinicalTrials.gov registry record · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 830
- Enrollment target
- 20
- Study locations
NCT06868277: Recruiting Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by AstraZeneca.
NCT06868277 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 830 participants, above the 317-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (162% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06868277, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 830 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Primary Outcome
OS is defined as the time from randomization until the date of death due to any cause.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Rilvegostomig
Study Locations (20)
Maryland
- Research Site - Bethesda
- Research Site - Frederick
- Research Site - Silver Spring
- Research Site - Towson
Florida
- Research Site - Bay Pines
- Research Site - Clearwater
- Research Site - St. Petersburg
Illinois
- Research Site - Chicago
- Research Site - Decatur
Iowa
- Research Site - Des Moines
- Research Site - Waterloo
Kentucky
- Research Site - Lexington
- Research Site - Owensboro
Delaware
- Research Site - Newark
Georgia
- Research Site - Marietta
Kansas
- Research Site - Leawood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 830 participants |
| Start Date | 2025-04-10 |
| Est. Completion | 2030-12-02 |
| Phase | Phase 3 |
What NCT06868277 shows while recruiting
NCT06868277 is an interventional study that assigns participants to a tested intervention. The registered 830 participants enrollment target is mid-sized for trials with a published cap, above the 317-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (162% higher).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06868277 names 20 study sites across 12 states, led by Maryland, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06868277 about?
NCT06868277 is a clinical study titled "A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer". The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
What is the current status of trial NCT06868277?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 830 participants. The study started on 2025-04-10. Estimated completion is 2030-12-02.
What conditions does trial NCT06868277 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT06868277?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Rilvegostomig (BIOLOGICAL).
Who is sponsoring clinical trial NCT06868277?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868277 being conducted?
This trial has 20 study locations across Delaware, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06868277's enrollment target sits among peer trials
830 11th of 130 higher than 120 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- NCT06910553 · 832 participants
IBD Pregnancy Registry
- NCT07089706 · 832 participants · Phase 4
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI